Literature DB >> 8495557

Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia.

T Kuzuya1, S Hoshida, N Yamashita, H Fuji, H Oe, M Hori, T Kamada, M Tada.   

Abstract

The infarct-limiting effect of ischemic preconditioning is believed to be a transient phenomenon. We examined the delayed effects of repetitive brief ischemia on limiting infarct size in an open-chest dog model by an occlusion (90 minutes) of the left anterior descending coronary artery (LAD) followed by reperfusion (5 hours). The dogs were preconditioned with four brief repeated ischemic episodes induced by 5-minute LAD occlusions with subsequent reperfusion. The size of infarcts initiated by a sustained occlusion immediately or 24 hours after preconditioning was significantly smaller when compared with infarcts in sham-operated dogs (for the immediate occlusion, 14.4 +/- 2.0% versus 39.0 +/- 3.7%, respectively [p < 0.01]; and for the delayed occlusion, 18.8 +/- 3.4% versus 35.1 +/- 4.6%, respectively [p < 0.05]); however, when the infarction was induced 3 hours (31.2 +/- 3.7% versus 37.5 +/- 4.2%, respectively) or 12 hours (25.4 +/- 4.8% versus 35.0 +/- 5.3%, respectively) after repetitive ischemia, the infarct size did not differ. No differences were seen in regional myocardial blood flow or rate-pressure products between the two groups. These results indicate that an infarct-limiting effect of brief repeated ischemia can be observed 24 hours after sublethal preconditioning.

Entities:  

Mesh:

Year:  1993        PMID: 8495557     DOI: 10.1161/01.res.72.6.1293

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  112 in total

Review 1.  Myocardial preconditioning: basic concepts and potential mechanisms.

Authors:  S Okubo; L Xi; N L Bernardo; K Yoshida; R C Kukreja
Journal:  Mol Cell Biochem       Date:  1999-06       Impact factor: 3.396

Review 2.  Therapeutic potential of ischaemic preconditioning.

Authors:  R J Edwards; A T Saurin; R D Rakhit; M S Marber
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 3.  Role of bradykinin in preconditioning and protection of the ischaemic myocardium.

Authors:  G F Baxter; Z Ebrahim
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

4.  NF-kappaB driven cardioprotective gene programs; Hsp70.3 and cardioprotection after late ischemic preconditioning.

Authors:  Michael Tranter; Xiaoping Ren; Tiffany Forde; Michael E Wilhide; Jing Chen; Maureen A Sartor; Mario Medvedovic; W Keith Jones
Journal:  J Mol Cell Cardiol       Date:  2010-07-16       Impact factor: 5.000

5.  Second window of preconditioning normalizes palmitate use for oxidation and improves function during low-flow ischaemia.

Authors:  Raymond K Kudej; Mathew Fasano; Xin Zhao; Gary D Lopaschuk; Susan K Fischer; Dorothy E Vatner; Stephen F Vatner; E Douglas Lewandowski
Journal:  Cardiovasc Res       Date:  2011-08-11       Impact factor: 10.787

6.  Reperfusion Injury: Basic Concepts and Protection Strategies.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

7.  Age-associated differences in gene expression in response to delayed anesthetic preconditioning.

Authors:  C Zhong; N Fleming; X Lu; P Moore; H Liu
Journal:  Age (Dordr)       Date:  2011-10-19

8.  Involvement of protein kinase C in the delayed cytoprotection following sublethal ischaemia in rabbit myocardium.

Authors:  G F Baxter; F M Goma; D M Yellon
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

9.  Overexpression of the rat inducible 70-kD heat stress protein in a transgenic mouse increases the resistance of the heart to ischemic injury.

Authors:  M S Marber; R Mestril; S H Chi; M R Sayen; D M Yellon; W H Dillmann
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Mechanism of cyclooxygenase-2 upregulation in late preconditioning.

Authors:  Yu-Ting Xuan; Yiru Guo; Yanqing Zhu; Hui Han; Robert Langenbach; Buddhadeb Dawn; Roberto Bolli
Journal:  J Mol Cell Cardiol       Date:  2003-05       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.